ACE inhibitors and ARBs: Managing potassium and renal function

被引：53

作者：

Momoniat, Tasnim ^{[1
]}

Ilyas, Duha ^{[1
]}

Bhandari, Sunil ^{[1
]}

Clin Edu, M. ^{[1
]}

机构：

[1] Hull Univ Teaching Hosp NHS Trust, Dept Nephrol, East Yorkshire, England

来源：

CLEVELAND CLINIC JOURNAL OF MEDICINE | 2019年 / 86卷 / 09期

关键词：

CONVERTING-ENZYME-INHIBITOR; CHRONIC KIDNEY-DISEASE; HEART-FAILURE; BLOOD-PRESSURE; SERUM POTASSIUM; TASK-FORCE; HIGH-RISK; HYPERKALEMIA; MORTALITY; ASSOCIATION;

D O I：

10.3949/ccjm.86a.18024

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) are used primarily to treat hypertension and are also useful for conditions such as heart failure and chronic kidney disease, independent of their effect on blood pressure. This article reviews the indications for ACE inhibitors and ARBs and offers advice for managing their adverse effects, particularly declining renal function and hyperkalemia.

引用

页码：601 / 607

页数：7

共 55 条

[1] Hyperkalemia in hospitalized patients -: Causes, adequacy of treatment, and results of an attempt to improve physician compliance with published therapy guidelines [J].

Acker, CG ;

Johnson, JP ;

Palevsky, PM ;

Greenberg, A .

ARCHIVES OF INTERNAL MEDICINE, 1998, 158 (08) :917-924

[2] PATHOPHYSIOLOGY OF POTASSIUM ABSORPTION AND SECRETION BY THE HUMAN INTESTINE [J].

AGARWAL, R ;

AFZALPURKAR, R ;

FORDTRAN, JS .

GASTROENTEROLOGY, 1994, 107 (02) :548-571

[3]

[Anonymous], MYOC INF CARD REH PR

[4]

[Anonymous], 2004, Am J Kidney Dis, V43, pS1, DOI DOI 10.1053/J.AJKD.2004.03.003

[5]

Asenjo RM, ANGIOTENSIN CONVERTI

[6] Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine - Is this a cause for concern? [J].

Bakris, GL ;

Weir, MR .

ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (05) :685-693

[7]

Barratt J, 2008, OXFORD DESK REFERENC

[8] Multicentre randomized controlled trial of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker withdrawal in advanced renal disease: the STOP-ACEi trial [J].

Bhandari, Sunil ;

Ives, Natalie ;

Brettell, Elizabeth A. ;

Valente, Marie ;

Cockwell, Paul ;

Topham, Peter S. ;

Cleland, John G. ;

Khwaja, Arif ;

El Nahas, Meguid .

NEPHROLOGY DIALYSIS TRANSPLANTATION, 2016, 31 (02) :255-261

[9] Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy [J].

Brenner, BM ;

Cooper, ME ;

de Zeeuw, D ;

Keane, WF ;

Mitch, WE ;

Parving, HH ;

Remuzzi, G ;

Snapinn, SM ;

Zhang, ZX ;

Shahinfar, S .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) :861-869

[10] Cardiovascular and Renal Outcomes of Renin-Angiotensin System Blockade in Adult Patients with Diabetes Mellitus: A Systematic Review with Network Meta-Analyses [J].

Catala-Lopez, Ferran ;

Macias Saint-Gerons, Diego ;

Gonzalez-Bermejo, Diana ;

Rosano, Giuseppe M. ;

Davis, Barry R. ;

Ridao, Manuel ;

Zaragoza, Abel ;

Montero-Corominas, Dolores ;

Tobias, Aurelio ;

de la Fuente-Honrubia, Cesar ;

Tabares-Seisdedos, Rafael ;

Hutton, Brian .

PLOS MEDICINE, 2016, 13 (03)

← 1 2 3 4 5 6 →